Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

RC Doebele, A Drilon, L Paz-Ares, S Siena… - The Lancet …, 2020 - thelancet.com
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
被引用次数：1485 相关文章

[引用][C] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

RC Doebele, A Drilon, L Paz-Ares… - The Lancet …, 2020 - portalcientifico.uah.es
Background: Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials

RC Doebele, A Drilon, L Paz-Ares… - The Lancet …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …

[引用][C] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

RC Doebele, A Drilon, L Paz-Ares, S Siena… - The Lancet …, 2020 - cir.nii.ac.jp
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours:
integrated analysis of three phase 1–2 trials | CiNii Research CiNii 国立情報学研究所 学術情報 …
[HTML] nih.gov

[HTML][HTML] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

RC Doebele, A Drilon, L Paz-Ares, S Siena… - The Lancet …, 2020 - ncbi.nlm.nih.gov
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

RC Doebele, A Drilon, L Paz-Ares, S Siena… - The Lancet …, 2019 - europepmc.org
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
[PDF] kimia-pharma.co

[PDF][PDF] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw… - 2019 - kimia-pharma.co
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

RC Doebele, A Drilon, L Paz-Ares, S Siena… - The Lancet …, 2020 - Elsevier
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw… - 2020 - ahro.austin.org.au
Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has
been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours …

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

RC Doebele, A Drilon, L Paz-Ares, S Siena… - 2020 - publications.goettingen-research …
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours:
integrated analysis of three phase 1–2 trials | GRO.publications Import Service | New here? Skip …